
    
      The endpoints of the study are to determine the response rate, complete response rate,
      duration of response, time to progression, time-to-treatment failure, safety, and survival
      following Iodine-131 Anti-B1 Antibody therapy in patients with NHL who previously responded
      (PR, CCR, or CR) with a duration of response of at least 3 months to Iodine-131 Anti-B1
      Antibody therapy.
    
  